You are here

Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Hartford, Connecticut, 06102-5037 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Smoking Cessation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
35-75 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Participants must have stable, documented cardiovascular disease (including at least
one of the following diagnosed > 2 months prior to the Screening visit - angina,
myocardial infarction (MI), revascularization, transient ischemic attack (TIA), and
peripheral vascular disease (PVD).

- Participants that smoke > 10 cigarettes / day.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Participants with unstable cardiovascular disease

- Cardiovascular events in the past 2 months

- Moderate or severe chronic obstructive pulmonary disease (COPD)

NCT00282984
Pfizer
Completed
Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now